Lifeline Scientific, Inc Additional Listing (8361Y)
28 2월 2013 - 4:02PM
UK Regulatory
TIDMLSI
RNS Number : 8361Y
Lifeline Scientific, Inc
28 February 2013
27 February 2013
Lifeline Scientific, Inc.
("Lifeline" or the "Company")
Admission of shares and TVR
Lifeline Scientific, the medical technology company, has
transferred 13,213 common shares of $0.01 each from Regulation S
restricted stock to unrestricted stock and admission is expected to
occur on 5 March 2013.
Lifeline has 19,424,959 common shares in issue and each share
has the right to one vote. Therefore for the purposes of the FSA
Disclosure and Transparency Rules the total number of voting rights
in the Company is 19,424,959.
The above figure may be used by shareholders as the denominator
for the calculations by which they will determine whether they are
required to notify the Company of their interests in, or change to
their interests in, Lifeline Scientific, Inc. under the FSA's
Disclosure and Transparency Rules.
Following this transfer, 6,717,805 common shares remain subject
to Regulation S restrictions and are held in certificated form
only. These common shares subject to Regulation S restrictions are
traded under ISIN number USU529641008.
The remaining 12,707,154 common shares have had the Regulation S
restrictions lifted and are held in uncertificated form trading
under ISIN number US53223V1017.
Enquiries:
Lifeline Scientific, Inc. +1 847 824 2436
Lisa Kieres, CFO
Seymour Pierce +44 (0)20 7107 8000
Mark Percy (Corporate Finance)
David Banks (Corporate Broking)
FTI Consulting +44 (0)20 7831 3113
Simon Conway / John Dineen
About LifePort Kidney Transporter
Created with the challenges of organ recovery and transport in
mind, LifePort Kidney Transporter is a proprietary medical device
designed to provide improved kidney preservation, evaluation and
transport prior to transplantation. Today, it is widely recognised
as the world's leading machine preservation device for kidneys.
Employed by surgeons in over 135 leading transplant programmes in
23 countries worldwide, LifePorts have successfully preserved over
38,000 kidneys intended for clinical transplant. The product
provides a sealed, sterile, protected environment where a solution
is gently pumped through the kidney at cold temperatures to
minimise damage while the organ is outside the body. LifePort is
lightweight and portable, allowing organs to be perfused from the
time of recovery until transplant. It is designed to travel
unaccompanied by land or air, safely transporting the kidneys
across town or between countries. While the kidney is being
perfused, LifePort records data on temperature, flow rate, vascular
resistance and pressure every 10 seconds providing surgeons with
additional data prior to transplant. LifePort is the only system
with clinical outcomes data produced from an independent,
prospective, randomised, statistically powered, multi-centre
clinical trial. Study results have been widely published in
scientific journals, including the New England Journal of Medicine.
Data indicates that patients receiving LifePort preserved kidneys
experienced significant reduction in the incidence and duration of
delayed graft function and increased graft survival at 1-year and
3-years post transplant. LifePort has also been recognised for its
design and engineering. It has received prominent awards for design
excellence from the medical device industry, has been selected for
exhibition at the Smithsonian Cooper-Hewitt, National Design Museum
and is part of the permanent Collection of The Museum of Modern Art
(MoMA) in New York City.
About Lifeline Scientific, Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product is the FDA cleared, CE marked and
clinically validated LifePort Kidney Transporter. Devices for
preservation of the liver, pancreas, heart, and lung are in late
stage pre-clinical development.
see www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISMMGZZNNRGFZM
Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
